Aperio Group LLC increased its stake in Eli Lilly And Co (NYSE:LLY) by 3.4% in the third quarter, HoldingsChannel reports. The institutional investor owned 579,608 shares of the company’s stock after acquiring an additional 19,269 shares during the period. Aperio Group LLC’s holdings in Eli Lilly And Co were worth $62,198,000 at the end of the most recent quarter.
A number of other hedge funds also recently added to or reduced their stakes in the stock. BB&T Corp raised its stake in Eli Lilly And Co by 5.8% in the third quarter. BB&T Corp now owns 29,747 shares of the company’s stock worth $3,193,000 after buying an additional 1,629 shares in the last quarter. Iowa State Bank bought a new position in shares of Eli Lilly And Co during the third quarter valued at approximately $225,000. First American Bank bought a new position in shares of Eli Lilly And Co during the third quarter valued at approximately $7,863,000. Nisa Investment Advisors LLC increased its stake in shares of Eli Lilly And Co by 29.0% during the third quarter. Nisa Investment Advisors LLC now owns 499,945 shares of the company’s stock valued at $53,640,000 after purchasing an additional 112,466 shares in the last quarter. Finally, Andra AP fonden increased its stake in shares of Eli Lilly And Co by 34.3% during the third quarter. Andra AP fonden now owns 103,800 shares of the company’s stock valued at $11,139,000 after purchasing an additional 26,500 shares in the last quarter. 76.56% of the stock is owned by institutional investors.
In other news, major shareholder Lilly Endowment Inc sold 185,000 shares of the stock in a transaction that occurred on Tuesday, July 24th. The shares were sold at an average price of $92.03, for a total transaction of $17,025,550.00. Following the sale, the insider now owns 121,631,601 shares in the company, valued at $11,193,756,240.03. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, SVP Alfonso G. Zulueta sold 7,000 shares of the stock in a transaction that occurred on Thursday, October 4th. The shares were sold at an average price of $114.64, for a total transaction of $802,480.00. Following the sale, the senior vice president now owns 45,224 shares in the company, valued at approximately $5,184,479.36. The disclosure for this sale can be found here. In the last quarter, insiders have sold 1,785,575 shares of company stock worth $180,166,130. Corporate insiders own 0.11% of the company’s stock.
Eli Lilly And Co (NYSE:LLY) last posted its quarterly earnings results on Tuesday, July 24th. The company reported $1.50 EPS for the quarter, beating the Zacks’ consensus estimate of $1.30 by $0.20. Eli Lilly And Co had a negative net margin of 0.60% and a positive return on equity of 39.84%. The firm had revenue of $6.36 billion for the quarter, compared to analysts’ expectations of $6.05 billion. During the same quarter in the prior year, the company posted $1.11 earnings per share. The business’s revenue for the quarter was up 9.1% on a year-over-year basis. As a group, equities analysts predict that Eli Lilly And Co will post 5.47 earnings per share for the current fiscal year.
The company also recently declared a quarterly dividend, which will be paid on Monday, December 10th. Stockholders of record on Thursday, November 15th will be issued a dividend of $0.5625 per share. This represents a $2.25 dividend on an annualized basis and a dividend yield of 1.98%. The ex-dividend date is Wednesday, November 14th. Eli Lilly And Co’s payout ratio is 52.57%.
LLY has been the subject of a number of analyst reports. Morgan Stanley raised their target price on shares of Eli Lilly And Co from $93.00 to $102.00 and gave the company an “equal weight” rating in a research note on Tuesday, July 31st. TheStreet downgraded shares of Eli Lilly And Co from a “b” rating to a “c+” rating in a research note on Friday, August 24th. Guggenheim initiated coverage on shares of Eli Lilly And Co in a research note on Monday, October 8th. They set a “buy” rating for the company. Cantor Fitzgerald reaffirmed a “buy” rating and set a $128.00 target price on shares of Eli Lilly And Co in a research note on Wednesday. Finally, Barclays reaffirmed an “overweight” rating and set a $112.00 target price (up previously from $107.00) on shares of Eli Lilly And Co in a research note on Tuesday, September 18th. One equities research analyst has rated the stock with a sell rating, six have given a hold rating and twelve have given a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus target price of $109.80.
About Eli Lilly And Co
Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates through two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.
Featured Article: Cash Flow
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly And Co (NYSE:LLY).
Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.